Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mRNA-3705 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| mRNA-3705 | EXPERIMENTAL | Participants will receive mRNA-3705 at the same dose levels at the same dosing interval (every 2 weeks \[Q2W\], or every 3 weeks \[Q3W\]) last received in the clinical study of mRNA-3705 in which they initially participated, unless the Sponsor recommends modification. |
| Name | Type | Description |
|---|---|---|
| mRNA-3705 | DRUG | A sterile liquid for injection |
Inclusion Criteria: * Completed the assigned dose regimen treatment time period in other clinical studies of mRNA-3705 or is eligible for early transition to this study because they missed more than 3 consecutive doses of study drug due to coronavirus disease 2019 (COVID-19) vaccination during Stud...
mRNA-3705 is an investigational therapy being developed for the treatment of methylmalonic acidemia, a rare inherited metabolic disorder. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
mRNA-3705 is being developed by Moderna, Inc., a biotechnology company traded on the Nasdaq under the ticker symbol MRNA. The company is conducting clinical trials to evaluate the safety and clinical activity of this investigational therapy.
mRNA-3705 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is recruiting participants to evaluate long-term safety and clinical activity.
mRNA-3705 is being studied in one clinical trial with the identifier NCT05295433. This is a Phase 1 extension study evaluating long-term safety and clinical activity in participants previously enrolled in other clinical studies of mRNA-3705. The trial is recruiting up to 56 participants with methylmalonic acidemia.
No, mRNA-3705 is not the same as methylmalonic acidemia. Methylmalonic acidemia is the disease condition that mRNA-3705 is being developed to treat. mRNA-3705 is an investigational drug candidate, not a disease.